International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: http://www.sciepub.com/journal/ijcd Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
Go
International Journal of Celiac Disease. 2016, 4(1), 19-23
DOI: 10.12691/ijcd-4-1-4
Open AccessReview Article

Gut-bone Cross Talks and Implications in Celiac Disease

Aaron Lerner1, 2, and Torsten Matthias2

1B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

2AESKU.KIPP Institute, Wendelsheim, Germany

Pub. Date: February 16, 2016

Cite this paper:
Aaron Lerner and Torsten Matthias. Gut-bone Cross Talks and Implications in Celiac Disease. International Journal of Celiac Disease. 2016; 4(1):19-23. doi: 10.12691/ijcd-4-1-4

Abstract

Metabolic bone disease is a frequent extra-intestinal co-morbidity in newly diagnosed, mostly adult patients who have 70% low bone mineral density. Musculoskeletal signs and symptoms, osteopenia, osteoporosis and fractures are the most frequent manifestations. The etiology is multifactorial, however, micronutrient malabsorption, mainly of calcium and vitamin D, secondary hyperparathyroidism and inflammation are the main driving forces. The diagnosis is based on signs and symptoms, biochemical and endocrinologic laboratory evaluation and imaging by dual x-ray absorptiometry. Treatment of low bone mineral density in CD comprises: a gluten free diet, coverage of nutritional deficiencies (including calcium and vitamin D), changes in life style and if necessary, pharmacologic and hormonal replacement therapy. The cost effectiveness of those therapy methods were barely assessed. Understanding the pathophysiology of bone loss in celiac disease might bring new therapeutical strategies for the patient’s benefit.

Keywords:
celiac disease bone osteopenia osteoporosis calcium vitamin D mineral density

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Lerner A, Blank M, Shoenfeld Y. Celiac disease and autoimmunity. Isr J Med Sci 1996;32:33-36.
 
[2]  Reif S, Lerner A. Celiac disease and infection. In: infections and Autoimmunity. Shoenfeld, Y. and Rose, N. (Eds), Elsevier B.V. 2004, pp.689-692.
 
[3]  Chmielewska A, Pieścik-Lech M, Szajewska H, Shamir R. Primary Prevention of Celiac Disease: Environmental Factors with a Focus on Early Nutrition. Ann Nutr Metab 2015; 67(suppl 2): 43-50.
 
[4]  Lerner A, Matthias T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev. 2015;14:479-89.
 
[5]  Lerner A. Factors affecting the clinical presentation and time diagnosis of celiac disease: The Jerusalem and the West Bank-Gaza experience (editorial). Isr J Med Sci 1994;30:294-295.
 
[6]  Lerner A. Non nutritional environmental factors associated with celiac disease: infections and vaccinations. In: vaccines and autoimmunity. Ed. Shoenfeld Y, Agmon-Levin N, Tomljenovic L. Wiley Blackwell Pub. P.301-306, 2015.
 
[7]  Lerner A, Reif S. Nonnutritional environmental factors associated with Celiac disease: The Infectome. In: Infections and Autoimmunity. Eds: Shoenfeld Y, Agmon-Levine N, Rose NR. 2nd Ed. Elsevier B.V. Chapter 50. 2015, pages 829-837.
 
[8]  Reif S, Lerner A. Tissue transglutaminase—the key player in celiac disease: a review. Autoimm Rev 2004;3:40-45.
 
[9]  Lerner A, Neidhöfer S, Matthias T. Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond: Part A: TG2 double-edged sword: gut and extraintestinal involvement. Immunome Research, In Press, 2015.
 
[10]  Shamir R, Eliakim R, Lahat N, Sobel E, Lerner A. ELISA assay of anti endomysial antibodies in the diagnosis of celiac disease: comparison with immunofluorescence assay of anti endomysial antibodies and tissue transglutaminase antibodies. Isr Med Assoc J. 2002;4:594-596.
 
[11]  Lerner A, Neidhöfer S, Matthias T. Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond. Part B: Anti- Transglutaminase 2 autoantibodies: friends or enemies. Immunome Research, In Press, 2015.
 
[12]  Rozenberg O, Lerner A, Pacht A, Grinberg M, Reginashvili D, Henig C, Barak M.A novel algorithm for childhood celiac disease serological diagnosis based upon intestinal biopsies. Crit Rev Allerg Immunol. 2012;42:331-341.
 
[13]  Lerner A, Neidhöfer S, Matthias T. Serological markers and/or intestinal biopsies in the case-finding of celiac disease. International Journal of Celiac Disease 2015;3:53-55.
 
[14]  Lerner A. Serological Diagnosis of Celiac Disease –Moving Beyond the Tip of the Iceberg. International Journal of Celiac Disease. 2014;2:64-66.
 
[15]  Lerner A. New therapeutic strategies for celiac disease. Autoimmun Rev. 2010;9:144-147.
 
[16]  Lerner A. Blank M. Hypercoagulability in celiac disease-an update. Autoimmun Rev. 2014;13:1138-1141.
 
[17]  Branski D, Ashkenazy A, Frier S, Lerner A, et al. Extra intestinal manifestation and associated disorders of celiac disease. In: Branski D, Rozen P, Kaganoff MF (eds) Gluten-sensitive enteropathy, from gastrointest res. Karger, Basel, 1992, pp 164-175.
 
[18]  Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurological disorders in patients with celiac disease. Pediatrics 2004;113:1672-1676.
 
[19]  Lerner A, Makhoul B, Eliakim R. Neurological manifestations of celiac disease in children and adults. Eur Neurolog J. 2012; 4: 15-20.
 
[20]  Lerner A, Matthias T. Rheumatoid arthritis-celiac disease relationship: joints get that gut feeling. Autoimm Rev. 2015: 14: 1038-47.
 
[21]  Lerner A, Matthias T. Increased knowledge and awareness of celiac disease will benefit the elderly. International Journal of Celiac Disease 2015;3:112-114.
 
[22]  Lerner A, Matthias T. Editorial: Celiac disease: intestinal, heart and skin inter-connections. International Journal of Celiac Disease 2015;3:28-30.
 
[23]  Capriles VD, Martini LA, Arêas JA. Metabolic osteopathy in celiac disease: importance of a gluten-free diet. Nutr Rev 2009;67:599-606.
 
[24]  Zanchi C, Di Leo G, Ronfani L, Martelossi S, Not T, Ventura A. Bone metabolism in celiac disease. J Pediatr 2008;153:262–265.
 
[25]  Bianchi ML, Bardella MT. Bone in celiac disease. Osteoporos Int 2008;19:1705-1716.
 
[26]  Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000;46(Suppl 1):1-8.
 
[27]  Turner J, Pellerin G, Mager D. Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis. J Pediatr Gastroenterol Nutr 2009;49:589-593.
 
[28]  Lewis NR, Scott BB. Should patients with coeliac disease have their bone mineral density measured? Eur J Gastroenterol Hepatol 2005;17:1065-1070.
 
[29]  Mora S. Celiac disease in children: impact on bone health. Rev Endocr Metab Disord 2008;9:123-130.
 
[30]  Olmos M, Antelo M, Vazquez H, Smecuol E, Mauriño E, Bai JC. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig Liver Dis 2008; 40:46-53.
 
[31]  Lerner A, Shapira Y, Agmon-Levin N, , Pacht A, Ben-Ami Shor D, López Hoyos M, Sanchez-Castanon, M, Shoenfeld Y. The clinical significance of 25OH-vitamin D status in celiac disease. Crit Rev Allerg Immunol. 2012;42:322-330.
 
[32]  Hartman C, Hino B, Lerner A, et al. Bone quantitative ultrasound and bone mineral density in children with celiac disease. J. Pediatr Gastrointerol. Nutr. 2004;39:504-510.
 
[33]  Ish Shalom S, Rozen GS, Lerner A. Osteoporosis: An Emerging Problem in Pediatrics. In: “Pediatric Nutrition”. Eds. Reifen RM, Lerner A, Branski D, Heymans ASA. Karger, Basel. pp.110-121, 1998.
 
[34]  Raggatt, L. J. Partridge NC. Cellular and Molecular Mechanisms of Bone Remodeling. J of Biolog Chemist 2010;285: 25103-25108.
 
[35]  Sims, NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit”. Bonekey Rep. 2014;3:481-490.
 
[36]  Sims NA, Vrahnas C.Regulation of cortical and trabecular bone mass by communication between osteoblasts, osteocytes and osteoclasts. Arch Biochem Biophys. 2014;561:22-8.
 
[37]  Stenson WF, Newberry R, Lorenz R, Baldus C, Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005;28:393-399.
 
[38]  Legroux-gerot I, Leloire O, Blanckaert F, Tonnel F et al. Screening for celiac disease in patients with osteoporosis. Joint Bone Spine 2009;76:162-165
 
[39]  Lucendo AJ, García-Manzanares A. Bone mineral density in adult coeliac disease: an updated review. Rev Esp Enferm Dig. 2013;105:154-162.
 
[40]  Younes M, Ben YH, Safer L, Fadoua H, Zrour S, Bejia I, et al. Prevalence of bone loss in adult celiac disease and associated factors: a control case study. Tunis Med 2012;90:129-135.
 
[41]  Corazza GR, Di SM, Maurino E, Bai JC. Bones in coeliac disease: diagnosis and treatment. Best Pract Res Clin Gastroenterol 2005;19:453-465.
 
[42]  Shahbazkhani B, Aletaha N, Khonche A, et al. Is it necessary to screen for celiac disease in adult idiopathic osteoporosis? Gastroenterol Hepatol Bed Bench. 2015;8:140-145.
 
[43]  43. Kavuncu V, Dundar U, Ciftci IH, et al. Is there any requirement for celiac disease screening routinely in postmenapausal women with osteoporosis? Rheumatol Int. 2009;29:841-845.
 
[44]  González D, Sugai E, Gomez JC, et al. Is it necessary to screen for celiac disease in postmenopausal osteoporotic women? Calcif Tissue Int. 2002;71:141-144.
 
[45]  Krupa-Kozak U. Pathologic bone alterations in celiac disease: etiology, epidemiology, and treatment. Nutrition. 2014;30:16-24.
 
[46]  Saturni L, Ferretti G, Bacchetti T. The gluten-free diet: safety and nutritional quality. Nutrients 2010;2:16-34.
 
[47]  Sdepanian VL, de Miranda Carvalho CN, de Morais MB, Colugnati FAB, Fagundes-Neto U. Bone mineral density of the lumbar spine in children and adolescent with celiac disease on a gluten free diet in Sao Paulo, Brazil. J Pediatr Gastroenterol Nutr 2003;37:571-6.
 
[48]  Caruso R, Pallone F, Stasi E, Romeo S, Monteleone G. Appropriate nutrient supplementation in celiac disease. Ann Med. 2013;45:522-531.
 
[49]  Fouda MA, Khan AA, Sultan MS, et al. Evaluation and management of skeletal health in celiac disease: position statement. Can J Gastroenterol. 2012;26:819-829.
 
[50]  Real A, Gilbert N, Hauser B, et al. Characterisation of osteoprotegerin autoantibodies in coeliac disease. Calcif Tissue Int. 2015;97:125-133.
 
[51]  Barera G, Mora S, Brambilla P, et al.Body composition in children with celiac disease and the effects of a gluten-free diet: a prospective case-control study. Am J Clin Nutr. 2000;72:71-75.
 
[52]  Szathmári M, Tulassay T, Arató A, et al. Bone mineral content and density in asymptomatic children with coeliac disease on a gluten-free diet. Eur J Gastroenterol Hepatol. 2001;13:419-424.
 
[53]  Larussa T, Suraci E, Nazionale I, et al. No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease. World J Gastroenterol. 2012;18:1622-1627.
 
[54]  Meyer D, Stavropolous S, Diamond B, et al.Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol. 2001;96:112-119.
 
[55]  Muzzo S, Burrows R, Burgueño M et al. Effect of calcium and vitamin D supplementation on bone mineral density of celiac children. Nutr Res. 2000;20:1241-1247.
 
[56]  Bertonazzi A, Nelson B, Salvador J, Umland E. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. Womens Health (Lond Engl). 2015 Nov 30. [Epub ahead of print].
 
[57]  Kumar M, Rastogi A, Bhadada SK, et al. Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study. Indian J Med Res. 2013;138:882-887.